Long-term follow-up of patients with Buerger’s disease after autologous stem cell therapyÇağdaş Baran, Serkan Durdu, Evren Özçınar, Mehmet Çakıcı, Ali Ihsan Hasde, Bahadır Inan, Mustafa Şırlak, Rüçhan AkarDepartment of Cardiovascular Surgery, Faculty of Medicine, Ankara University; Ankara-Turkey
Objective: We investigated the long-term results of autologous bone marrow mononuclear cells (ABMMNCs) implantation in patients with Buerger’s disease (BD). Methods: Twenty-eight patients (25 males and 3 females) who had BD and critical unilateral limb ischemia were investigated between April 2003 and August 2005. The patients were administered multiple injections of CD34+ and CD45+ positive ABMMNCs into the gastrocnemius muscle, the intermetatarsal region, and the dorsum of the foot (n=26) or forearm (n=2) and saline injection into the contralateral limb. Results: The mean follow-up time was 139.6±10.5 months. No complication related to stem cell therapy was observed during the follow-up. The ankle–brachial pressure index evaluated at 6 months and 120 months was compared to the baseline scores (p<0.001 and p=0.021, respectively). Digital subtraction angiography (DSA) was performed for all patients at baseline, 6 months, and 120 months. The angiographic improvement was 78.5% and 57.1% at 6 and 120 months, respectively. Patients demonstrated a significant improvement in the quality of life parameters at 6 months compared to baseline (p=0.008) and 120 months compared to the baseline (p=0.009). The 10-year amputation-free rate was 96% (95% CI=0.71-1) in ABMMNC-implanted limbs and 93% (95% CI=0.33–0.94) in saline-injected limbs (p=1). Conclusion: Autologous stem cell therapy could be an alternative therapeutic method for BD at long-term follow-up. Keywords: Buerger’s disease, stem cell therapy, autologous bone marrow mononuclear cell
Çağdaş Baran, Serkan Durdu, Evren Özçınar, Mehmet Çakıcı, Ali Ihsan Hasde, Bahadır Inan, Mustafa Şırlak, Rüçhan Akar. Long-term follow-up of patients with Buerger’s disease after autologous stem cell therapy. Anatol J Cardiol. 2019; 21(3): 155-162
Corresponding Author: Serkan Durdu, Türkiye |
|